A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Etoposide (VP-16–213)

1985 • 361 citations

SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIA

1973 • 148 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.

1975 • 133 citations

VM 26 and VP 16–213: A comparative analysis

1977 • 122 citations

Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

1983 • 114 citations

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

1976 • 102 citations

VP-16-213 (etoposide): The mandrake root from Issyk-Kul

1982 • 79 citations

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

1986 • 73 citations

Variable bioavailability following repeated oral doses of etoposide

1985 • 65 citations

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1987 • 63 citations

High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.

1987 • 54 citations

Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

1982 • 50 citations

A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry

1981 • 48 citations

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

1987 • 47 citations

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide

1985 • 34 citations

High-dose etoposide (VP-16) in small-cell lung cancer.

1985 • 23 citations

Extensive stage small cell carcinoma of the bronchus

1987 • 20 citations

The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review

1980 • 17 citations

VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.

1985 • 16 citations

Etoposide infusions for treatment of metastatic lung cancer.

1984 • 12 citations